Most Recent
The ACCC has taken a major wholesale supplier of sporting goods to court for allegedly setting minimum prices for cycling and sporting goods in its agreements with retailers.
Piper Alderman has struck back at a sex discrimination lawsuit brought by a former administrative assistant, admitting that while a law firm partner did tell her to "go spend time with your kids" following a meeting in which she was made redundant, the comment had been taken out of context.
The Nine Network has lost its challenge to a $3.7 million defamation judgment awarded to a prominent Queensland family over a 60 Minutes report that implied they were to blame for a 2011 flood event that killed 12 people.
The director of the besieged Mayfair investment group will submit a new noteholder proposal to the court in an effort to stave off the winding up of M101 Nominees and salvage his multi-million dollar Dunk Island and Mission Beach investments.
One of the lead applicants in a class action against ratings giant S&P Global, which is involved in a dispute with the funder that's backing the case, wants to look at the funding agreement signed by the class action's other lead applicant.
A court has hit Network Ten with indemnity costs after finding the broadcaster "buried" a defamation notice on its website in a manner designed to "frustrate or undermine" a settlement agreement reached with a gay American social media personality.
Pharmaceutical company Boehringer Ingelheim will take another crack at opposing a patent application for an injectable anti-parasite drug for livestock by a subsidiary of competitor Merck Sharp & Dohme.
In a win for ASIC, a judge has found that former oil and gas company Antares Energy violated its continuous disclosure obligations by failing to reveal the name of the buyer behind an ill-fated US$254 million acquisition of Texan oil assets.
The Australian Taxation Office has secured a Full Federal Court victory in its $60 million tax battle with Healius, overturning a ruling that found the healthcare company could claw back a multi-million dollar tax refund.
The Federal Court has upheld Novartis' appeal of a ruling revoking its patent for an oral form of multiple sclerosis drug Gilenya, after Australian generic drug maker Arrow Pharmaceuticals dropped its opposition to the patent despite prevailing before IP Australia.